```html

Berger Disease (IgA Nephropathy) – A Complete Patient‑Focused Guide

Overview

Berger disease, more formally known as IgA nephropathy (IgAN), is a chronic kidney disorder characterized by the deposition of immunoglobulin A (IgA) antibodies in the glomeruli—the tiny filtering units of the kidneys. The immune complexes trigger inflammation and scarring, which can progressively impair kidney function.

Who it affects

• Most commonly diagnosed in adolescents and young adults (teens‑30s).
• Both sexes are affected, with a slight male predominance (approximately 1.3–1.5 : 1).<sup>[1]</sup>
• Higher prevalence in East Asian populations (especially Japan, China, and Korea) compared with Western countries; the overall global prevalence is estimated at 2–5 cases per 100,000 people per year.<sup>[2]</sup>

Why it matters – Up to 30 % of patients progress to end‑stage renal disease (ESRD) within 20–25 years of diagnosis, making early recognition and management crucial.<sup>[3]</sup>

Symptoms

IgA nephropathy often presents subtly, and many people are first identified after a routine urine test. When symptoms do appear, they may include:

1. Hematuria (blood in the urine)

• Gross hematuria: Dark tea‑ or cola‑colored urine, often concurrent with an upper‑respiratory infection (“synpharyngitic” hematuria).
• Microscopic hematuria: Detectable only on lab analysis; may be persistent.

2. Proteinuria (protein in the urine)

• Mild to moderate amounts (often <300 mg/day) early on; can increase over time.
• Nephrotic‑range proteinuria (>3 g/day) occurs in a minority but signals higher risk of progression.

3. Edema

• Swelling of the ankles, feet, or around the eyes, usually when protein loss is substantial.

4. Hypertension

• Elevated blood pressure is both a symptom and a driver of kidney damage.

5. Decreased kidney function

• Elevated serum creatinine or reduced estimated glomerular filtration rate (eGFR). Often asymptomatic until later stages.

6. Flank pain (rare)

• Occasional dull discomfort in the lower back, typically unrelated to IgAN but may coexist with other kidney conditions.

Causes and Risk Factors

Underlying Mechanism

IgA nephropathy is an autoimmune‑mediated disease. In most cases, the body produces abnormally glycosylated IgA1 molecules that are recognized as foreign, leading to the formation of immune complexes. These complexes deposit in the mesangial area of glomeruli, triggering inflammation, proliferation of mesangial cells, and eventually scarring (glomerulosclerosis).

Genetic predisposition

• Family clustering is documented; first‑degree relatives have a 2–3 % risk vs. <0.1 % in the general population.<sup>[4]</sup>
• Genome‑wide association studies (GWAS) have identified variants in the HLA‑DRB1, CFHR1‑3, and DEFA loci that increase susceptibility.

Environmental & lifestyle triggers

• Respiratory or gastrointestinal infections: The classic “synpharyngitic” hematuria often follows a sore throat or sinus infection.
• Smoking: Associated with faster progression to ESRD.<sup>[5]</sup>
• High‑salt diet: Exacerbates hypertension and proteinuria.

Other risk factors

• Male sex
• Asian ethnicity (especially Japanese)
• Co‑existing autoimmune diseases (e.g., celiac disease, inflammatory bowel disease)
• Use of certain medications (e.g., non‑steroidal anti‑inflammatory drugs) that can worsen kidney injury.

Diagnosis

Step‑wise approach

1. Medical history & physical exam – Focus on episodes of hematuria, recent infections, blood pressure, and family history.
2. Urine studies
   • Urinalysis: red blood cells, dysmorphic RBCs, protein.
   • Urine protein‑to‑creatinine ratio (UPCR) to quantify protein loss.
3. Blood tests
   • Serum creatinine, eGFR, electrolytes.
   • Complement levels (C3, C4) – usually normal in IgAN, helping differentiate from lupus nephritis.
4. Imaging
   • Renal ultrasound – assesses kidney size, rules out obstruction.
5. Kidney biopsy (definitive test)
   • Performed under ultrasound guidance.
   • Light microscopy shows mesangial proliferation; immunofluorescence reveals dominant IgA deposits; electron microscopy confirms location.
   • Biopsy provides the Oxford classification (MEST‑C score) that predicts prognosis and guides therapy.<sup>[6]</sup>

When a biopsy may be deferred

• Typical presentation with isolated microscopic hematuria, normal kidney function, and low proteinuria—some clinicians monitor with periodic labs instead of immediate biopsy.

Treatment Options

1. General measures

• Blood pressure control – Target < 130/80 mmHg (KDIGO 2021 guidelines). Angiotensin‑converting enzyme inhibitors (ACEi) or angiotensin‑II receptor blockers (ARBs) are first‑line because they lower proteinuria and protect glomeruli.<sup>[7]</sup>
• Low‑sodium diet – <2 g of salt per day reduces hypertension and proteinuria.
• Smoking cessation – Improves overall cardiovascular and renal outcomes.
• Weight management & regular exercise – Aim for BMI 18.5–24.9 kg/m².

2. Pharmacologic therapy

Immunosuppression

• Corticosteroids – Oral prednisone (0.5–0.8 mg/kg/day) for 6–12 months can reduce proteinuria and slow eGFR decline in patients with proteinuria >1 g/day and preserved kidney function (eGFR >50 mL/min/1.73 m²).<sup>[8]</sup>
• Mycophenolate mofetil (MMF) – May be used as steroid‑sparing or in steroid‑refractory cases; evidence is mixed but shows benefit in Asian cohorts.
• Cyclophosphamide – Reserved for rapidly progressive IgAN with crescents on biopsy.
• Tonsillectomy – Performed mainly in Japan; some studies suggest reduced hematuria frequency, but the practice is controversial.

Targeted agents (emerging)

• Budecalisib (SGLT2 inhibitor) – Recent RCTs (e.g., DAPA‑GLY) show a 30 % reduction in kidney‑failure events in patients with proteinuric CKD, including IgAN.
• Baricitinib (JAK‑STAT inhibitor) – Phase 2 trial showed decreased proteinuria; still investigational.

3. Procedures

• Renal replacement therapy – Dialysis or kidney transplantation when eGFR falls <15 mL/min/1.73 m².
• Plasmapheresis – Considered in rare rapidly progressive cases with severe crescentic disease.

4. Lifestyle modifications (reinforced)

• Hydration – Aim for 1.5–2 L of fluid daily unless contraindicated.
• Limit protein intake to 0.8–1.0 g/kg body weight if proteinuria is >1 g/day (under dietitian guidance).
• Avoid nephrotoxic agents: NSAIDs, contrast dyes, high‑dose vitamin C.

Living with Berger Disease (IgA Nephropathy)

Monitoring schedule

• Every 3–6 months: Blood pressure, serum creatinine/eGFR, urinalysis, UPCR.
• Annually: Lipid profile, eye exam (if on steroids), bone density (if long‑term steroids).

Practical daily tips

• Medication adherence – Set alarms or use pill organizers; never stop ACEi/ARB without consulting your doctor.
• Dietary log – Track sodium and protein; many apps provide kidney‑friendly recipes.
• Physical activity – Moderate aerobic exercise (150 min/week) helps control blood pressure.
• Vaccinations – Stay up‑to‑date with influenza, COVID‑19, pneumococcal, and hepatitis B vaccines; immunosuppressed patients have higher infection risk.
• Stress management – Mindfulness, yoga, or counseling can improve adherence and blood pressure.

Support resources

• National Kidney Foundation (NKF) – patient education and support groups.
• Kidney Disease: Improving Global Outcomes (KDIGO) guidelines – for clinicians, but also patient-friendly summaries.
• Local transplant or CKD clinics – often provide multidisciplinary teams (nephrologist, dietitian, social worker).

Prevention

Because IgAN has a genetic component, primary prevention is limited. However, actions that reduce kidney stress can delay onset or progression:

• Prompt treatment of upper‑respiratory or gastrointestinal infections – some clinicians prescribe short courses of antibiotics for recurrent streptococcal infections, though evidence is modest.
• Adopt a heart‑healthy, low‑salt diet from childhood.
• Avoid smoking and excessive alcohol consumption.
• Maintain optimal blood pressure and body weight.
• Use NSAIDs sparingly; prefer acetaminophen for pain when appropriate.

Complications

• Chronic kidney disease progression → End‑stage renal disease (ESRD) – Requires dialysis or transplantation.
• Hypertension‑related cardiovascular disease – Heart failure, stroke, myocardial infarction.
• Thrombotic events – Nephrotic‑range proteinuria increases clot risk.
• Infections – Immunosuppressive therapy predisposes to bacterial, viral, and fungal infections.
• Medication side‑effects – Steroid‑induced diabetes, osteoporosis, cataracts; ACEi/ARB‑related hyperkalemia.
• Pregnancy complications – Pre‑eclampsia and accelerated loss of kidney function in women with significant proteinuria.

When to Seek Emergency Care

References

1. Kidney Disease: Improving Global Outcomes (KDIGO). Clinical Practice Guideline for Glomerulonephritis. 2021.
2. Yoshikawa N, et al. Epidemiology of IgA nephropathy in Asia. Kidney Int Rep. 2020;5(6):1021‑1030.
3. Lok CE, et al. Long‑term outcomes in IgA nephropathy. NEJM. 2017;376:2573‑2584.
4. Gharavi AG, et al. Familial IgA nephropathy: genetics and clinical outcomes. Clin J Am Soc Nephrol. 2019;14(4):523‑534.
5. Zhang L, et al. Smoking accelerates progression of IgA nephropathy. Am J Kidney Dis. 2018;71(6):825‑833.
6. Levy AP, et al. The Oxford classification of IgA nephropathy: validation and clinical use. Kidney Int. 2009;76(1):76‑85.
7. KDIGO 2021 Blood Pressure Guideline Committee. Kidney Int Suppl. 2021;11(1):1‑115.
8. Rauen T, et al. Corticosteroid treatment in IgA nephropathy – a meta‑analysis. Lancet. 2022;399(10328):1865‑1877.
9. Barbour S, et al. SGLT2 inhibition in IgA nephropathy (DAPA‑GLY). J Am Soc Nephrol. 2023;34(9):2105‑2116.

```